All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
MDM2 inhibitors
MDM2 inhibitors
TP53 inactivation can occur by different mechanisms, such as MDM2/MDMX upregulation and downstream effects of NPM1 and FLT3 mutations; therefore, the targeting of these pathways is being investigated in the clinical setting. Blocking the MDM2-TP53 interaction with inhibitors, such as idasanutlin, KRT-232, or APG-115, can prevent the proteasomal degradation of TP53 and reinstate apoptosis mechanisms.
Save to your areas of interest